Elanco Animal Health Inc (ELAN) · Nov 6, 2026 · Earnings
Beat — Adjusted EPS $0.27 vs ~$0.20 consensus; revenue $1.265B vs ~$1.21B
Elanco earnings beat consensus, with Zenrelia and Credelio Quattro driving growth, margins and another full-year guidance raise.
Elanco is in a product-led growth transition: it is trying to replace older portfolio pressure with newer pet-health launches, while integrating AHV International and reducing leverage. The prior quarter had already established a beat-and-raise pattern, with innovation products and faster deleveraging becoming the central operating story.
This was a broad operational beat, not just a low-quality EPS surprise. Revenue reached $1.265 billion, ahead of the published consensus of roughly $1.21 billion, while adjusted EPS was $0.27 versus approximately $0.20 expected. Adjusted EBITDA also grew 23% year over year to $243 million, supported by stronger pricing and mix.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Financial Highlights) | $1,265M (+11%) | $1,137M | ~$1,210M |
| Adjusted EBITDA (Financial Highlights) | $243M (+23%) | $198M | |
| Adjusted EPS (Financial Highlights) | $0.27 (+42%) | $0.19 | ~$0.20 |
The underlying mix was especially constructive. Pet Health grew 14% organically, with Zenrelia and Credelio Quattro continuing to gain clinic adoption and share; Farm Animal was slower but still grew organically. Poultry remained the notable weak spot, down 7%, but it was outweighed by the faster-growing pet and ruminant businesses.
Management converted the quarter’s outperformance into a meaningful guidance raise. The new full-year midpoint is about $5.168 billion of revenue, $1.058 billion of adjusted EBITDA and $1.185 of adjusted EPS, up from roughly $5.115 billion, $1.023 billion and $1.13 previously. This is more than a routine reaffirmation: the company also lifted expected 2026 organic constant-currency growth to approximately 8% from 6%-7% and raised its expected margin improvement.
| November 2026 guidance | August 2026 guidance | |
|---|---|---|
| Revenue (Full-Year Guidance) | $5,155M-$5,180M | $5,090M-$5,140M |
| Adjusted EBITDA (Full-Year Guidance) | $1,050M-$1,065M | $1,010M-$1,035M |
| Adjusted EPS (Full-Year Guidance) | $1.17-$1.20 | $1.10-$1.16 |
The balance-sheet improvement adds credibility to the operating progress. Net leverage reached 2.9x at quarter-end, earlier than expected, giving Elanco more flexibility to allocate capital while continuing to fund launches and R&D. That matters because the growth plan still depends on sustained investment rather than simple cost cutting.
Bottom line: Elanco delivered a genuine beat across sales and adjusted profit, with its newer pet-health products driving the upside and management raising the full-year bar again. The story is strengthening from portfolio transition to demonstrated execution, although poultry weakness and continued launch spending remain secondary offsets.
Q4 results and 2027 outlook, early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!